...
首页> 外文期刊>Journal of Clinical Ultrasound: JCU >Hypoechoic focal liver lesions: Characterization with contrast enhanced ultrasonography.
【24h】

Hypoechoic focal liver lesions: Characterization with contrast enhanced ultrasonography.

机译:低回声性肝脏局灶性病变:超声造影增强特征。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To evaluate the late sinusoidal phase of contrast enhancement with a 2nd-generation ultrasound contrast enhanced medium in the characterization of hypoechoic focal liver lesions. METHODS: We studied 88 hypoechoic liver lesions (diameter range, 1-18 cm; with 18 lesions 2 cm or less) found on conventional grayscale sonography (US) with contrast-enhanced ultrasonography (CEUS). Final diagnosis was made using contrast enhanced helical CT, contrast enhanced MR, angiography (DSA), and/or histopathic confirmation or clinical imaging follow-up. RESULTS: There were 37/88 benign lesions demonstrated: 17 cavernous hemangiomas, 3 capillary hemangiomas, 11 focal nodular hyperplasias (FNH), 3 focal areas of sparing in hepatic steatosis, 2 adenomas, and 1 intrahepatic necrotic area. Malignant lesions demonstrated included 51/88: 27 hepatocellular carcinomas (HCC) in cirrhosis, 11 metastatic carcinomas, 10 metastatic endocrine tumors, 2 cholangiocellular carcinomas (CCC) and 1 non-Hodgkin's lymphoma (NHL). CEUS characterized 30/37 (81%) benign lesions and 45/51 (88%) malignant lesions. On the basis of the results obtained during the sinusoidal contrast enhanced phase of CEUS, diagnosis of benignancy was possible in 35/37 (95%) of benign liver lesions and diagnosis of malignancy in 49/51 (96%) of malignant liver lesions. The enhancement pattern of 13 small (< or = 2 cm in diameter) hypervascular liver lesions (3 capillary hemangiomas, 2 FNHs, 4 HCCs, 4 metastatic endocrine tumors) was better demonstrated on CEUS than on helical CT. In these cases the hyper vascularization of the lesions shown on CEUS was not confirmed on CT. CONCLUSIONS: CEUS distinguished malignant from benign hypoechoic liver lesions with an accuracy of 95%. (c) 2005 Wiley Periodicals, Inc. J Clin Ultrasound 33:164-172, 2005.
机译:目的:在第二代超声造影增强剂中评价低回声性局灶性肝损害的特征,以评估后期增强的正弦曲线相位。方法:我们研究了常规灰阶超声(US)和对比增强超声(CEUS)发现的88例低回声性肝病灶(直径范围1-18 cm; 18个病灶2 cm或更小)。使用造影剂增强型螺旋CT,造影剂增强型MR,血管造影(DSA)和/或组织病理学证实或临床影像学随访进行最终诊断。结果:显示出37/88个良性病变:17个海绵状血管瘤,3个毛细血管血管瘤,11个局灶性结节性增生(FNH),3个肝脂肪变性的局灶性区域,2个腺瘤和1个肝内坏死区域。证实的恶性病变包括51/88:肝硬化中的27例肝细胞癌(HCC),11例转移性癌,10例转移性内分泌肿瘤,2例胆管细胞癌(CCC)和1例非霍奇金淋巴瘤(NHL)。 CEUS鉴定为30/37(81%)良性病变和45/51(88%)恶性病变。根据在CEUS的正弦对比增强阶段获得的结果,良性肝病变中35/37(95%)可以诊断为良性,恶性肝病变中49/51(96%)可以诊断为恶性。在CEUS上比在螺旋CT上更好地证实了13个小直径(<或= 2 cm)的高血管肝病变(3个毛细血管血管瘤,2个FNH,4个HCC,4个转移性内分泌肿瘤)的增强模式。在这些情况下,在CT上未证实CEUS上显示的病变的过度血管形成。结论:CEUS可将恶性与良性低回声性肝病区分开,准确率为95%。 (c)2005 Wiley Periodicals,Inc. J Clin Ultrasound 33:164-172,2005。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号